Bluejay Diagnostics, Inc.

Listed Company

BJDXCIK 0001704287NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-6.85M

Total Assets

$7.12M

Equity

$5.98M

Shares Out

972.2K

Op. Cash Flow

$-6.05M

Business

Bluejay Diagnostics, Inc. develops rapid diagnostic tests for critical care settings based on its Symphony technology platform, an analyzer and single-use cartridges. Its main product candidate is the Symphony IL-6 immunoassay for measuring interleukin-6 to monitor disease progression in sepsis, and it also maintains a subsidiary for the ALLEREYE point-of-care allergic conjunctivitis test. Key business activities include platform and cartridge development, clinical studies and regulatory interactions, and contractual manufacturing and licensing arrangements. It targets U.S. critical care markets (ERs, ICUs) and plans sales via direct and distributor channels, financing arrangements for devices, and cartridge consumable sales, with potential research-use sales.

Summary from filing dated 2025-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	3	3	6	4	1
General and administrative	4	4	4	5	2
Sales and marketing	—	8,297	283,443	451,421	289,726
Total operating expenses	7	7	10	9	3
Operating loss	−7	−7	−10	−9	−3
Interest expense	−839	−823,028	—	—	—
Interest income	97,559	145,823	164,900	—	—
Other income, net	7,769	129,027	192,429	168,464	—
Total other income (expense), net	104,489	−548,178	357,329	20,828	−258,135
Net loss	−7	−8	−10	−9	−3
Deemed dividend on warrant modification	—	13	—	—	—
Net loss applicable to common stockholders	−7	−21	−10	—	—
Net Loss per share to common stockholders Basic (in Dollars per share)	−15.25	−456.75	−3,631	−9.22	−0.41
Net Loss per share to common stockholders Diluted (in Dollars per share)	−15.25	−456.75	−3,631	−9.22	−0.41
Weighted average common shares outstanding Basic (in Shares)	449,043	45,848	2,741	1	9
Weighted average common shares outstanding Diluted (in Shares)	449,043	45,848	2,741	1	9

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	5	4	2	10	19
Prepaid expenses and other current assets	275,957	596,938	747,263	2	2
Assets held for sale	22,770	—	—	—	—
Total current assets	5	5	3	12	21
Property and equipment, net	2	2	1	1	337,366
Operating lease right-of-use assets	113,289	209,788	333,267	465,514	—
Other non-current assets	7,905	35,257	28,663	35,211	21,019
Total assets	7	7	5	14	21
Accounts payable	214,255	145,122	491,474	635,818	295,778
Operating lease liability, current	100,000	113,260	162,990	168,706	—
Accrued expenses	804,942	551,986	1	835,730	341,384
Total current liabilities	1	810,368	2	2	637,162
Operating lease liability, non-current	20,211	108,989	189,987	323,915	—
Other non-current liabilities	4,540	8,567	12,321	15,823	—
Total liabilities	1	927,924	2	2	637,162
Commitments and contingencies (Note 10)	—	—	—	—	—
Common stock, $0.0001 par value; 250,000,000 shares authorized; 604,534 and 138,503 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	60	14	—	101	2,011
Additional paid-in capital	47	40	30	29	—
Accumulated deficit	−42	−35	−27	−17	−8
Total stockholders equity	6	6	3	12	20
Total liabilities and stockholders equity	7	7	5	14	21

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation expense	74,182	75,618	648,708	156,598	—
Stock-based compensation expense	6	20,094	189,245	433,004	—
Amortization of right-of-use asset	96,499	123,479	132,247	149,770	—
Non-cash interest expense for note payable	—	307,563	—	—	—
Write-off and impairment of property and equipment	42,937	3,411	1,787	237,309	—
Prepaid expenses and other current assets	333,881	150,325	926,217	−40,772	—
Deferred offering costs	—	265,081	—	—	—
Other non-current assets	27,352	−6,594	6,548	−14,192	−21,019
Accounts payable	69,133	−346,352	−235,760	298,881	−79,150
Accrued expenses and other current and non-current liabilities	150,918	−695,653	−30,279	336,620	—
Net cash used in operating activities	−6	−8	−8	−8	−4
Purchase of property and equipment	−173,735	−306,783	−704,166	−1	−23,947
Net cash used in investing activities	−173,735	−306,783	−704,166	−1	−23,947
Proceeds from issuance of common stock, gross	8	12	2	—	—
Payment for issuance costs of common stock	−1	−2	−413,544	—	—
Proceeds from issuance of notes payable	—	2	—	—	—
Repayment of notes payable	—	−2	—	—	−289,617
Proceeds from exercise of Class D warrants	—	558	—	—	9,079
Fractional shares adjustment for reverse stock split	—	−395	—	—	—
Payment of finance lease	−4,027	−3,754	−4,807	−801	—
Net cash provided by financing activities	7	10	1	8,075	23
Net increase in cash and cash equivalents	862,930	2	−8	−9	—
Fair value of common stock issued in connection with notes payable	—	307,563	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro